Oncolytics Biotech (ONCY) Competitors $1.25 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.26 +0.01 (+0.80%) As of 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCY vs. IVA, ESPR, ERAS, KOD, CYRX, ETON, BCYC, CMPS, CMPX, and RGNXShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Inventiva (IVA), Esperion Therapeutics (ESPR), Erasca (ERAS), Kodiak Sciences (KOD), CryoPort (CYRX), Eton Pharmaceuticals (ETON), Bicycle Therapeutics (BCYC), COMPASS Pathways (CMPS), Compass Therapeutics (CMPX), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry. Oncolytics Biotech vs. Its Competitors Inventiva Esperion Therapeutics Erasca Kodiak Sciences CryoPort Eton Pharmaceuticals Bicycle Therapeutics COMPASS Pathways Compass Therapeutics REGENXBIO Inventiva (NASDAQ:IVA) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership. Do institutionals and insiders believe in IVA or ONCY? 19.1% of Inventiva shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts recommend IVA or ONCY? Inventiva presently has a consensus price target of $14.83, indicating a potential upside of 146.81%. Oncolytics Biotech has a consensus price target of $5.00, indicating a potential upside of 300.00%. Given Oncolytics Biotech's higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than Inventiva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inventiva 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Oncolytics Biotech 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is IVA or ONCY more profitable? Inventiva's return on equity of 0.00% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets InventivaN/A N/A N/A Oncolytics Biotech N/A -438.11%-143.90% Which has preferable earnings & valuation, IVA or ONCY? Oncolytics Biotech has lower revenue, but higher earnings than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInventiva$9.20M62.51-$199.34MN/AN/AOncolytics BiotechN/AN/A-$23.14M-$0.27-4.63 Does the media refer more to IVA or ONCY? In the previous week, Inventiva had 4 more articles in the media than Oncolytics Biotech. MarketBeat recorded 8 mentions for Inventiva and 4 mentions for Oncolytics Biotech. Inventiva's average media sentiment score of 0.64 beat Oncolytics Biotech's score of 0.50 indicating that Inventiva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, IVA or ONCY? Inventiva has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. SummaryInventiva beats Oncolytics Biotech on 9 of the 12 factors compared between the two stocks. Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCY vs. The Competition Export to ExcelMetricOncolytics BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$125.45M$3.07B$5.65B$10.29BDividend YieldN/A2.36%5.68%4.62%P/E Ratio-4.6320.7675.8426.11Price / SalesN/A403.84517.46171.31Price / CashN/A45.9137.5661.52Price / Book25.009.6212.876.30Net Income-$23.14M-$52.73M$3.29B$271.03M7 Day Performance-8.09%0.64%-0.26%-0.15%1 Month Performance26.42%6.31%3.84%6.41%1 Year Performance38.94%18.97%68.35%28.81% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCYOncolytics Biotech2.4391 of 5 stars$1.25flat$5.00+300.0%+38.9%$125.45MN/A-4.6330IVAInventiva3.0601 of 5 stars$6.02+6.5%$14.83+146.4%+153.2%$540.49M$9.95M0.00100Gap UpESPREsperion Therapeutics3.9824 of 5 stars$2.51-5.6%$7.00+178.9%+47.3%$536.32M$332.31M-5.12200News CoverageERASErasca2.4719 of 5 stars$1.78-3.3%$3.71+108.7%-24.7%$521.95MN/A-3.96120KODKodiak Sciences2.8518 of 5 stars$15.01+57.5%$10.50-30.0%+493.5%$503.39MN/A-3.9590News CoverageAnalyst ForecastGap UpHigh Trading VolumeCYRXCryoPort3.6902 of 5 stars$10.13+1.6%$12.56+23.9%+20.3%$499.17M$228.38M7.621,186Positive NewsETONEton Pharmaceuticals2.0585 of 5 stars$18.37+0.2%$29.67+61.5%+246.6%$491.83M$39.01M-114.8120Positive NewsBCYCBicycle Therapeutics3.502 of 5 stars$7.13+2.9%$22.22+211.7%-67.9%$480.29M$35.28M-2.03240CMPSCOMPASS Pathways2.7454 of 5 stars$5.04+2.9%$16.29+223.1%-20.4%$470.11MN/A-2.74120Positive NewsCMPXCompass Therapeutics2.62 of 5 stars$3.49+2.9%$13.88+297.6%+104.1%$468.78M$850K-7.7620RGNXREGENXBIO4.6156 of 5 stars$9.06+1.9%$28.38+213.2%-14.9%$449.07M$83.33M-2.63370Positive News Related Companies and Tools Related Companies Inventiva Competitors Esperion Therapeutics Competitors Erasca Competitors Kodiak Sciences Competitors CryoPort Competitors Eton Pharmaceuticals Competitors Bicycle Therapeutics Competitors COMPASS Pathways Competitors Compass Therapeutics Competitors REGENXBIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCY) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ONCY Stock Alerts